EXINI Diagnostics AB was established in 1999 to commercialize AI methods for automated analysis of diagnostic images developed by a research group at Lund University. As a certified medical device manufacturer, EXINI has developed automated analysis platforms for cardiac, brain and bone scans. The company has always been innovative, developing web-based systems in the early 2000s. EXINIs most widely distributed platform is used to calculate the automated Bone Scan Index, which quantifies the bone tumor burden in patients with metastatic prostate cancer. This platform has been installed at about 1,000 hospitals worldwide. In 2015, EXINI was acquired by Progenics Pharmaceuticals Inc. for developing patient centric AI technologies for PSMA-targeted theranostic agents.
Progenics develops innovative medicines and other technologies to target and treat cancer. Progenics’ pipeline includes: 1) therapeutic agents designed to precisely target cancer (AZEDRA, PSMA TTC and 1095), 2) PSMA-targeted imaging agents for prostate cancer (1404 and PyL™), and 3) imaging analysis technology. Progenics has two commercial products, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, which is partnered with Bausch Health Companies, Inc.; and AZEDRA, for the treatment of unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma (rare neuroendocrine tumors of neural crest origin) who require systemic anticancer therapy.
Chairman of the board
Mark R. Baker
Aseem Anand, PhD
Quality assurance is at the center of EXINI Diagnostics’ core business. The foundation of the company is the medical tradition of evidence-based research. Being a part of the health care sector also demands that the company upholds a high standard of quality in its products and services.
EXINI Diagnostics has a certified Quality Management System in accordance with ISO 13485:2016 and certificate of compliance with European Council Directive MDD 93/42EEC concerning medical devices. The Notified Body TÜV SÜD, Germany is responsible for this conformity assessment. EXINI Diagnostics’ product aBSI is CE marked.
EXINI has also implemented the FDA quality system regulation, 21 CFR Part 820 in our Quality Management System. Our legacy product EXINI, marketed as EXINI BoneBSI has a FDA 510(k) clearance (K122205). The web based version, aBSI was cleared in the United States in August 2019 (K191262).
Additionally our procedures follow all other applicable laws, regulations and guidelines in Europe, USA and other markets in which we are represented.